key: cord-0822959-tlxeo7d6
authors: Bowman, Emily R; Cameron, Cheryl M Ainslie; Avery, Ann; Gabriel, Janelle; Kettelhut, Aaren; Hecker, Michelle; Ute Sontich, Claudia; Tamilselvan, Banumathi; Nichols, Carmen N; Richardson, Brian; Cartwright, Michael; Funderburg, Nicholas T; Cameron, Mark J
title: Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 may be predictive of death in Severe Coronavirus Disease 2019 (COVID-19)
date: 2020-11-29
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa744
sha: a501341308da4cafdd488327c72ab5cb4da2bdc9
doc_id: 822959
cord_uid: tlxeo7d6

People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) display a wide range of illness, from asymptomatic infection to severe respiratory distress resulting in death. We measured serum biomarkers in uninfected individuals and in individuals with mild, moderate, or critical COVID-19 disease. Levels of monocyte activation (sCD14 and FABP4) and inflammation (TNFR1 and 2) were increased in COVID-19 individuals, regardless of disease severity. Among patients with critical disease, individuals who recovered from COVID-19 had lower levels of TNFR1 and TNFR2 at hospital admission compared to these levels in patients with critical disease that ultimately died.

course [1] . A significant proportion of individuals with COVID-19 experience damage to their lungs, heart, or kidneys [2] , even if their disease course is not severe. There is a growing body of literature describing profiles of immune responses to SARS-CoV-2 that may relate to disease severity, but our understanding of how the immune activation may result in clearance of the virus or induce tissue damage and death is incomplete. Severe COVID-19 appears to be associated with increased inflammatory cytokines and markers of endothelial cell activation and coagulation [3, 4] . Recently, several immune phenotypes were identified in COVID-19; a subset of infected individuals with severe disease showed increased T and B cell activation, while others with severe disease had minimal lymphocyte activation [5] .

We have reported on the immune response to severe acute respiratory syndrome (SARS) [6] and here, we explored immune activation in COVID-19. In this cross sectional and longitudinal study, we examined serum levels of immune activation and inflammation, A c c e p t e d M a n u s c r i p t 4 activation over time, while patients who did not recover tended to maintain elevated levels of monocyte activation and inflammation. Interestingly, biomarkers associated with CVD and obesity (lipoprotein-associated phospholipase A2 (Lp-Pla2), oxidized low-density lipoprotein (OxLDL), adiponectin) were not associated with severity of disease or death.

COVID-19 participants were enrolled at MetroHealth Medical Center in Cleveland, OH, and provided informed consent (IRB 20-00198). Disease severity was classified based on oxygen requirements and the need for mechanical ventilation. Patients who did not need oxygen supplementation were categorized as "mild", patients who required oxygen were categorized as "moderate", and those who were intubated were categorized as "critical".

Control participants were recruited from the general population of the Ohio State University (OSU); experiments were performed in compliance with OSU IRBs 2014H0467 and 2020H0339.

Blood samples were collected in serum separating tubes (SST; BD Biosciences) and centrifuged for 10 minutes at 1000 x g. Serum was collected and frozen at -80C until thawed once and analyzed in batch. Samples from COVID-19 patients were collected at hospital admission (approximately), prior to treatment, and longitudinally. A c c e p t e d M a n u s c r i p t 5

Differences in biomarker levels between groups were determined using nonparametric t tests. Changes in longitudinal timepoints from COVID-19 patients were analyzed by paired t tests (GraphPad Prism 6).

Demographic information for control (N=14) and COVID-19 (N=44) study participants is provided in Supplemental Table 1 . We measured levels of OxLDL, adiponectin, and Lp-PLA 2 , as these markers are associated with CVD, obesity, and diabetes, and these comorbid conditions predict more severe COVID-19 [1] . Levels of these markers were not different between the COVID-19 patients and controls ( Morbidity and mortality in COVID-19 is also associated with hyperinflammation and a better understanding of how inflammatory biomarker levels relate to differential clinical outcomes in COVID-19 patients is important. Serum levels of monocyte and macrophage activation, sCD14 (2964 ng/mL v 1495 ng/mL, p<0.0001), sCD163 (1072 ng/mL v 644 ng/mL, p=0.01), and FABP4 (52,969 pg/mL v 18,733 pg/mL, p=0.0001), were increased in COVID-19 patients compared to levels in controls (Figure 1) . COVID-19 patients with critical disease who ultimately died displayed higher levels of sCD14 and FABP4 than did critical disease patients who recovered and patients with more mild disease (Figure 2) .

Additionally, we observed a significant decrease in sCD14 levels over time in A c c e p t e d M a n u s c r i p t 6 patients with moderate disease, whereas critical patients who died did not display similar reductions in sCD14 (Supplemental Figure 3) . Although sCD163 levels at initial time points did not differ among disease categorizations, we observed a significant increase in sCD163 serum concentrations over time only in patients who ultimately died (Supplemental Figure   3 ).

Markers of systemic inflammation (TNFR1; 2980 pg/mL v 1063 pg/mL, p=0.003) and

TNFR2 (7797 pg/mL v 1694 pg/mL, p<0.0001) were increased in COVID-19 patients, and

were associated with disease severity (Figure 1, 2) . Upon initial evaluation following hospital admission, serum concentrations of TNFR1 and TNFR2 were higher in critical patients who ultimately died compared to concentrations in critical patients who recovered.

Levels of TNFR1 and 2 were also increased in patients with mild to moderate disease compared to levels in controls (Figure 2) . Furthermore, COVID-19 patients with mild to moderate disease displayed reduced levels of TNFR1 and TNFR2 over time; we did not observe similar decreases in concentrations of these markers in critical patients.

Critically ill patients with COVID-19 display a broad spectrum of T and B cell activation [5] , suggesting that lymphocyte activation may not accurately predict disease course in COVID-19. Here, we report that elevated biomarkers of monocyte activation and inflammation may be associated with severe disease outcomes in COVID-19 patients.

Compared to levels measured in controls, levels of the monocyte/macrophage activation markers, sCD14, sCD163, and FABP4, were increased in patients with SARS-CoV-2.

Levels of TNFR1 and TNFR2 were also increased in COVID-19 patients, and at the time of hospital admission, prior to treatment, levels of these markers were elevated in patients with critical disease who ultimately died compared to levels in critical patients who recovered.

Furthermore, sCD14 levels were directly correlated with TNFR1 (p=0.005; r=0.433) and TNFR2 (p=0.0004; r=0.600). These findings suggest that markers of monocyte activation A c c e p t e d M a n u s c r i p t 7 and levels of inflammatory biomarkers TNFR1 and TNFR2 are associated with disease severity and may be predictive of mortality in critically ill patients.

Soluble CD14 levels were also associated with LBP (p=0.018; r=0.373).

can invade the intestinal tract, causing GI dysfunction [7] . Increased inflammatory responses also disrupt intestinal barriers leading to translocation of microbial products, which can amplify systemic inflammation [8] . Our data implicate monocyte/macrophage activation as a potential contributor to deaths related to critical COVID-19 infection. Monocyte activation is associated with mortality and cardiovascular risk in the general population and in people with HIV (PWH) [9, 10] . We have reported associations between sCD14 and HIV viremia, microbial translocation, and proinflammatory lipid profiles [11] ; the mediators of increased levels of sCD14 levels in COVID-19 should be identified. Monocytes are made up of distinct subgroups based on CD14 and CD16 expression [12] . Proportions of "inflammatory" CD14 + CD16 + monocytes are increased in PWH, sepsis, diabetes, and CVD [11, 13] . We have also reported that CD16 + monocytes in PWH and in people without HIV who have recently experienced an acute coronary event express high levels of tissue factor (TF), a A c c e p t e d M a n u s c r i p t 8 procoagulant molecule that correlates with plasma D-dimer levels. Patrolling monocytes (CD14 Dim CD16 + ) recognize viral products [12, 13] and express high levels of the fractalkine receptor (CX3CR1) which may cause these cells to home to the vascular endothelium.

COVID-19 is associated with vascular inflammation and coagulopathy [1, 2] , including increased levels of D dimer and fractalkine [3] . Induction of TF expression following recognition of viral products, and the ability of these cells to migrate to the endothelium, [14] . Dexamethasone may inhibit the upstream signaling that leads to TNF production A c c e p t e d M a n u s c r i p t 9 and may also inhibit the downstream effects of TNF: TNF receptor engagement. Further study on treatments aimed at inhibition of TNF in COVID-19 are needed.

Our study has limitations. The control group and COVID-19 patients were not ideally matched based on age and ethnicity. COVID-19 patients also had increased incidence of diabetes and hypertension relative to the controls, and patients with critical disease tended to be male (Supplemental Table 2 Although we did not observe alterations in markers associated with obesity (adiponectin), oxidative stress (OxLDL), and vascular inflammation (Lp-PLA 2 ) in the severity of COVID-19 participants, more expansive future studies might demonstrate associations with these indices and morbidity/mortality. We report the incidence of several other underlying conditions in this cohort, but none were especially related to disease severity (Supplemental Table 2 ). Interpretation of these findings in a larger study are needed, yet, our data suggest that activation of monocytes/macrophages and TNF-associated signaling cascades may be prognostic of disease course in COVID-19. Exploring relationships among specific immune activation profiles, COVID-19 symptoms, and end organ involvement, may enhance clinical care.

A c c e p t e d M a n u s c r i p t 10

Dr. Funderburg has served as a consultant for Gilead.

This work was supported by a generous donation from The Nord Family Foundation A c c e p t e d M a n u s c r i p t

The hallmarks of COVID-19 disease

Extrapulmonary manifestations of COVID-19

Elevated Serum Endothelial Cell Adhesion Molecules Expression in COVID-19 Patients

Cytokine release syndrome in severe COVID-19

Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

Novel coronavirus infection and gastrointestinal tract

Microbial Translocation Across the GI Tract

Plasma levels of soluble CD14 independently predict mortality in HIV infection

Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals

Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons

Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors

Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

We would like to express our gratitude to the staff at MetroHealth Medical Center who cared for the COVID-19 patients and obtained research samples. We also want to express our gratitude to the patients and their family members who selflessly agreed to take part in this research study.Corresponding Author Contact: mjc230@case.edu Alternate Corresponding Author Contact: Nicholas.Funderburg@osumc.edu

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t